B of A Securities Upgrades 10x Genomics: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
B of A Securities upgraded 10x Genomics (NASDAQ:TXG) to Neutral with a new price target of $54.00, up from the previous target of $36.00. TXG shares are currently trading up 2.26% at $49.23, and the new target suggests a potential upside of 9.69%. 10x Genomics is a life science technology company that generates most of its revenue from consumables.
December 12, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
10x Genomics was upgraded by B of A Securities to Neutral with a raised price target of $54.00, suggesting a potential upside of 9.69% from the current price.
Upgrades by major securities firms typically lead to positive short-term price movement as they reflect improved confidence in the company's fundamentals or market position. The increase in the price target suggests that B of A Securities sees more value in the stock than previously estimated, which could lead to increased investor interest and a rise in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100